Get the Stockscreener App
75.35
2.36%
1.61
Dexcom Inc stock is traded at $75.35, with a volume of 4.20M.
It is up +2.36% in the last 24 hours and up +23.03% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$73.74
Open:
$73.49
24h Volume:
4.20M
Relative Volume:
0.82
Market Cap:
$29.09B
Revenue:
$4.82B
Net Income/Loss:
$930.40M
P/E Ratio:
32.23
EPS:
2.3381
Net Cash Flow:
$1.43B
1W Performance:
+4.69%
1M Performance:
+23.03%
6M Performance:
+18.83%
1Y Performance:
-12.03%
1-Day Range:
$72.50
$76.34
1-Week Range:
$69.60
$76.34
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
75.39 | 28.45B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
87.25 | 149.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.26 | 116.96B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
74.10 | 94.76B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
47.87 | 71.81B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
88.81 | 49.79B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
Dexcom Inc. stock (US2521311074): shares trade mixed as investors look beyond latest earnings and gu - AD HOC NEWS
Dexcom Inc. stock (US2521311074): institutional buying and technical picture on Nasdaq - AD HOC NEWS
Stolen medical devices that failed quality control were sold to the public - Yahoo
Elliott to get two board seats at Dexcom ahead of investor day - MSN
DexCom Inc. stock underperforms Friday when compared to competitors - MSN
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Dexcom Inc. stock (US2521311074): shares edge lower after recent Nasdaq volatility - AD HOC NEWS
Dexcom, Inc. 8-K Filing Summary: Company Details, Stock Info, and Regulatory Compliance (May 27, 2026) - Minichart
DXCM News | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DXCM Stock Price, Quote & Chart | DEXCOM INC (NASDAQ:DXCM) - ChartMill
DexCom, Inc. (DXCM) Announces Results of 2026 Annual Meeting of Stockholders - GuruFocus
Dexcom Shareholders Approve Board, Auditor and Compensation - TipRanks
Dexcom (NASDAQ: DXCM) investors approve board slate, auditor and executive pay - Stock Titan
Dexcom Discovers Theft of Scrapped G7 CGM Sensors - Medical Product Outsourcing
Citigroup Adjusts Price Target on DexCom to $84 From $79, Maintains Buy Rating - marketscreener.com
Signos raises $20M, expands Dexcom partnership for weight loss - qz.com
Dexcom says some CGM sensors intended for scrap stolen and resold - MSN
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Dexcom (NASDAQ: DXCM) CEO has shares withheld to cover RSU taxes - Stock Titan
Dexcom (DXCM) EVP has 1,451 shares withheld for RSU tax obligations - Stock Titan
Dexcom (NASDAQ: DXCM) CFO has 1,451 RSU shares withheld for taxes - Stock Titan
Dexcom (NASDAQ: DXCM) EVP shares withheld to cover RSU tax obligations - Stock Titan
Dexcom (DXCM) EVP Coleman has 7,362 shares withheld to cover RSU taxes - Stock Titan
Elliott strikes Dexcom board settlement after taking stake - MSN
Signos, Inc announced that it has received $20 million in funding from GV Management Company, LLC, DexCom, Inc., Blue Cross and Blue Shield of Alabama - marketscreener.com
How The DexCom (DXCM) Investment Story Is Shifting With New Guidance And Valuation Resets - Yahoo Finance
Signos grows foothold in weight loss wave fueled by GLP-1s with its AI health data tracking - CNBC
Signos, Inc., Maker of the First FDA-cleared CGM System for Weight Management, Raises $20 Million to Accelerate Growth - Business Wire
TD Cowen Maintains DexCom(DXCM.US) With Buy Rating, Maintains Target Price $75 - Moomoo
Goldman Sachs Adjusts Price Target on DexCom to $85 From $80, Maintains Buy Rating - marketscreener.com
DexCom Faces Product Safety Incident, Stock Drops 4% - GuruFocus
Dexcom (DXCM) chair’s 10b5-1 sale leaves 382,482 shares held - Stock Titan
Dexcom recalls stolen G7 sensors sold by unauthorized vendor By Investing.com - Investing.com India
DexCom (DXCM) Alerts Customers About Stolen G7 Sensors - GuruFocus
Dexcom warns of scrapped glucose sensors being resold - MedTech Dive
Dexcom warns patients as stolen glucose sensors hit the market - Reuters
Dexcom recalls stolen G7 sensors sold by unauthorized vendor - Investing.com UK
DexCom Reports Theft of Scrapped G7 Glucose Monitor Sensors - marketscreener.com
Dexcom uncovers theft of scrapped product, notifies potentially impacted users - marketscreener.com
Dexcom Inc. stock (US2521311074): diabetes-tech player draws fresh fund flows and cautious optimism - AD HOC NEWS
Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users - The Joplin Globe
DXCM to launch Dexcom Flex CGM system for type 2 diabetes in Germany - MSN
Dexcom’s SWOT analysis: stock faces competitive headwinds in 2026 By Investing.com - Investing.com India
Dexcom’s SWOT analysis: stock faces competitive headwinds in 2026 - Investing.com UK
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings Signal Potential Upside - DirectorsTalk Interviews
Dexcom stock (US2521311074): earnings beat and fresh institutional interest keep CGM story in focus - AD HOC NEWS
How Dexcom Inc. (DXCM) Affects Rotational Strategy Timing - Stock Traders Daily
DexCom, Inc.Common Stock (Nasdaq:DXCM) Stock Quote - FinancialContent
Does DexCom’s (DXCM) Flex Launch in Germany Hint at a Broader CGM Access Strategy Shift? - simplywall.st
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):